A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer.
Int J Cancer
; 153(8): 1501-1511, 2023 10 15.
Article
in En
| MEDLINE
| ID: mdl-37357950
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Head and Neck Neoplasms
/
Antineoplastic Agents
Type of study:
Etiology_studies
Limits:
Humans
Language:
En
Journal:
Int J Cancer
Year:
2023
Type:
Article